^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    iopofosine I-131 (CLR 131)

    i
    Other names: CLR 131, CLR-1404, HOT 131-I-NM404 , CLR 1404 I-131, I-131-CLR1404, NM404, CLR1404 I-131, HOT, I-131-CLR1404, 131I-CLR1404
    Company:
    Cellectar
    Drug class:
    Beta radiation emitter
    Related drugs:
    8ms
    CLOVER-WaM: Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Cellectar Biosciences, Inc. | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial primary completion date
    |
    iopofosine I-131 (CLR 131)
    8ms
    Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, Cellectar Biosciences, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD34 (CD34 molecule)
    |
    iopofosine I-131 (CLR 131)
    8ms
    Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Cellectar Biosciences, Inc. | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Sep 2022 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    iopofosine I-131 (CLR 131)
    1year
    CLOVER-WaM: Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Cellectar Biosciences, Inc. | Trial completion date: Jun 2025 --> Dec 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date
    |
    iopofosine I-131 (CLR 131)
    over1year
    CLR 131 Combined With Radiation for Head and Neck Cancer (clinicaltrials.gov)
    P1, N=12, Completed, University of Wisconsin, Madison | Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Feb 2024
    Trial completion • Trial completion date
    |
    iopofosine I-131 (CLR 131)
    almost2years
    CLOVER-WaM: Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (clinicaltrials.gov)
    P2, N=120, Recruiting, Cellectar Biosciences, Inc. | Active, not recruiting --> Recruiting
    Enrollment open
    |
    iopofosine I-131 (CLR 131)
    almost2years
    CLOVER-WaM: Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Cellectar Biosciences, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    iopofosine I-131 (CLR 131)
    almost2years
    Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG (clinicaltrials.gov)
    P1, N=50, Recruiting, Cellectar Biosciences, Inc. | Not yet recruiting --> Recruiting | Phase classification: P1b --> P1
    Enrollment open • Phase classification
    |
    CD34 (CD34 molecule)
    |
    iopofosine I-131 (CLR 131)
    over2years
    Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG (clinicaltrials.gov)
    P1b, N=50, Not yet recruiting, Cellectar Biosciences, Inc. | Initiation date: May 2023 --> Oct 2023
    Trial initiation date
    |
    CD34 (CD34 molecule)
    |
    iopofosine I-131 (CLR 131)
    over2years
    CLR 131 Combined With Radiation for Head and Neck Cancer (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, University of Wisconsin, Madison | Trial completion date: Sep 2023 --> Jul 2024
    Trial completion date
    |
    iopofosine I-131 (CLR 131)
    over2years
    Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Cellectar Biosciences, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD34 (CD34 molecule)
    |
    iopofosine I-131 (CLR 131)
    almost3years
    Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG (clinicaltrials.gov)
    P1b, N=50, Not yet recruiting, Cellectar Biosciences, Inc. | Trial completion date: Dec 2026 --> Sep 2026 | Initiation date: Nov 2022 --> May 2023 | Trial primary completion date: Sep 2026 --> May 2026
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    iopofosine I-131 (CLR 131)